Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Loading Pathway...

Retinoic acid receptor RXR-alpha Apolipoprotein A-V Lipoprotein lipase Apolipoprotein C-III Peroxisome proliferator- activated receptor alpha Acyl-coenzyme A synthetase ACSM2A, mitochondrial Long-chain fatty acid transport protein 1 Acetyl-CoA carboxylase 1 Apolipoprotein A-I Apolipoprotein A-II Apolipoprotein A-I Apolipoprotein A-II Apolipoprotein B-100 Long-chain fatty acid transport protein 1 Lipoprotein lipase Gemfibrozil transporter Gemfibrozil nuclear transporter Retinoic acid receptor RXR-alpha Gemfibrozil Gemfibrozil Gemfibrozil H2O Magnesium Fatty Acids HDL VLDL Fatty Acids Fatty Acids Triglyceride Fatty Acid Diacylglycerol Lipoprotein lipase Apolipoprotein A1 Apolipoprotein A2 Apolipoprotein C3 Apolipoprotein B-100 Apolipoprotein A5 Acyl-coenzyme A synthetase Fatty acid transport protein 1 Acetyl-CoA carboxylase Transcription/Translation Fatty Acid Biosynthesis Transcription/Translation HDL Synthesis Transcription/Translation Transcription/Translation vLDL Synthesis Fatty acid metabolism Peroxisome proliferator- activated receptor alpha Biotin Manganese Nucleus Cytosol 1. Gemfibrozil activates the PPAR alpha receptor in nucleus. PPAR alpha combines with the RXR alpha receptor. This complex regulates gene transcription and translation 2. There is a decreased expression of enzymes involved in fatty acid biosynthesis, leading to a reduction in fatty acid 3. There is an increased expression of fatty acid transporters and metabolic enzymes which remove fatty acid from the blood and breaks it down in the mitochondria 4. There is an increased expression of enzymes which a part of HDL and are essential to HDL synthesis, thus increasing plasma levels of HDL 5. There is decreased expression of proteins that form part of vLDL, thus decreasing vLDL levels 6. There is upregulation of enzymes involved in lipolysis and downregulation of enzymes which inhibit triglyceride catabolism
Nucleus RXRA APOA5 LPL APOC3 PPARA ACSM2A SLC27A1 ACACA APOA1 APOA2 APOA1 APOA2 APOB SLC27A1 LPL Unknown Unknown RXRA Gemfibrozil Gemfibrozil Gemfibrozil Water Fatty Acids HDL VLDL Fatty Acids Fatty Acids Triglyceride Fatty Acid Diacylglycerol Lipoprotein lipase Apolipoprotein A1 Apolipoprotein A2 Apolipoprotein C3 Apolipoprotein B-100 Apolipoprotein A5 Acyl- coenzyme A synthetase Fatty acid transport protein 1 Acetyl-CoA carboxylase Transcription/Translation Fatty Acid Biosynthesis Transcription/Translation HDL Synthesis Transcription/Translation Transcription/Translation vLDL Synthesis Fatty acid metabolism PPARA
RXRA APOA5 LPL APOC3 PPARA ACSM2A SLC27A1 ACACA APOA1 APOA2 APOA1 APOA2 APOB SLC27A1 LPL RXRA Lopid Lopid Lopid H2O Mg2+ FA HDL VLDL FA FA TG FA Diacylg Lip lip Apol A1 Apo A2 Apol C3 Ap B-10 Apol A5 A-c A s F a t Ac-Co c PW000455 PW000167 PW000455 HDL Syn PW000455 PW000455 vLD Syn Fa ac m PPARA Biotin Mn2+ Nucleus Cytosol 1. Gemfibrozil activates the PPAR alpha receptor in nucleus. PPAR alpha combines with the RXR alpha receptor. This complex regulates gene transcription and translation 2. There is a decreased expression of enzymes involved in fatty acid biosynthesis, leading to a reduction in fatty acid 3. There is an increased expression of fatty acid transporters and metabolic enzymes which remove fatty acid from the blood and breaks it down in the mitochondria 4. There is an increased expression of enzymes which a part of HDL and are essential to HDL synthesis, thus increasing plasma levels of HDL 5. There is decreased expression of proteins that form part of vLDL, thus decreasing vLDL levels 6. There is upregulation of enzymes involved in lipolysis and downregulation of enzymes which inhibit triglyceride catabolism